

Topical Collection

Stem Cell Therapies for Treating Diabetes

Message from the Collection Editors

As of 2019, more than 463 million people in the world live with diabetes. This is a serious threat to global health and is certainly a big issue in terms of economic impact. In the past decades, there has been active research into using stem cell therapy to treat diabetes, such as type 1 or type 2 diabetes. Since the discovery and identification of various types of stem cells in the human body, there have been immense efforts to generate human pancreatic islets or insulin-producing beta cells from these varied stem cells, for the purpose of restoring euglycemia. More recently, methodologies to make human islet or beta-like cells have matured significantly. It appears that the human stem cell field is very close to using stem cell-derived islets or beta cells to treat or even cure diabetes. In view of these significant advances and 2021 being the 100th anniversary for the discovery of insulin, we decided to commission this timely Special Issue, in the hope that stem cell-based therapy will pave the way for the next century in moving the field closer toward an eventual cure for diabetes.

Collection Editors

Dr. Jun Shirakawa

Yokohama City University, Yokohama, Japan

Dr. Adrian Kee Keong Teo

Institute of Molecular and Cell Biology (IMCB), A*STAR; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore



Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



mdpi.com/si/41973

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).